Detalhe da pesquisa
1.
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
Blood
; 143(21): 2178-2189, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394665
2.
De Novo Variants in CNOT1, a Central Component of the CCR4-NOT Complex Involved in Gene Expression and RNA and Protein Stability, Cause Neurodevelopmental Delay.
Am J Hum Genet
; 107(1): 164-172, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32553196
3.
Characterization of a novel MEF2D-BCL9 fusion-positive acute lymphoblastic leukemia cell line.
Haematologica
; 108(10): 2859-2864, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37051743
4.
Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
Blood Adv
; 8(8): 1835-1845, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38386975
5.
ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia.
Hemasphere
; 7(10): e967, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37736661